Swiss start-up enables fastest mitral valve chordal repair

17.05.2018 13:54
Heart

Swiss medtech startup CoreMedic has announced the start of a first-in-man “Chagall” study to evaluate new minimally-invasive valve repair technology. CoreMedic’s flagship product ChordArt is a transfemoral system for mitral valve chordal repair in the beating heart and represents a less invasive procedure compared to the current surgical methods.

CoreMedic is developing ChordArt, a novel repair system to address unmet needs in the treatment of degenerative heart disease with mitral valve insufficiency, the most common valve pathology affecting more than 7 million patients worldwide. The ChordArt implant is used to replace the ruptured or elongated chordae of the valve and reestablishes the connection of the valve leaflets with the papillary muscle to restore the proper function. As ChordArt reduces the complexity of the procedure, both patients and physicians will benefit. The first-in-man (FIM) case using ChordArt was treated by the Heart Team led by Prof. Kęstutis Ručinskas at the Vilnius University Hospital, Lithuania. The ChordArt treatment was aimed at improving procedural outcomes and allowing standardized placement of the artificial chords with a dedicated, reproducible technique. The patient recovered very well from the intervention and is continuously doing well. A 30 day follow-up showed no complications.

Fast, safe and precise procedure
“Using the ChordArt reduced the invasiveness and duration of the procedure by repairing the valve in a fast, precise and safe way. This allowed the Heart Team to focus on the procedure and timing rather than manually placing the artificial chords to resolve the mitral insufficiency” said Dr. Alberto Weber, Herzzentrum Hirslanden, Zurich, Switzerland, who proctored the procedure. “Thanks to the ease of the ChordArt deployment technique, this was the fastest mitral valve chordal repair I have ever witnessed.”

The “Chagall” Trial is a prospective, multicenter, first-in-man study intended to establish the safety and effectiveness of the ChordArt System. The study was approved to enroll up to 40 subjects at up to 6 European centers. This study is the first trial of its kind to treat patients that have ruptured or elongated mitral chords with the ChordArt System.

(Press relesase)

Picture: yodiyim / Fotolia.com

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.